Cytoreductive therapy in pediatric patients with essential thrombocythemia
Pediatric Hematology/Oncology and Immunopathology · 14.04.2026 · 25 (1) · 60-67
DOI: 10.24287/j.1086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Hematology/Oncology and Immunopathology, online erschienen am 14.04.2026. Verfasst von P. V. Kralichkin und 3 weiteren Autor:innen. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The drugs of choice for the treatment of adult patients with essential thrombocythemia (ET) include hydroxycarbamide (HC), anagrelide, interferon alpha (IFN-a), or pegylated interferon alpha (PEG-IFN-a). In a pediatric cohort, there is still no consensus regarding either the indications for treatment initiation or the choice of first-line treatment. The aim of the study was to evaluate the efficacy and safety of cytoreductive therapy in pediatric patients with ET. Materials and methods. The study included 24 patients diagnosed with ET in whom driver mutations in the JAK2 and CALR genes were verified. Interferon therapy was administered to 14 children: IFN-a (n = 2) at a dose of 2 000 000–3 000 000 IU subcutaneously 2–3 times a week; PEG-IFN-a (n = 12) at a dose of 1.5–3.0 μg/kg subcutaneously once a week. HC therapy at a dose of 10–20 mg/kg/day orally was administered to 8 children, anagrelide at a dose of 1.5–2.0 mg/day orally – to 1 child, and ruxolitinib at a dose of 30 mg/day orally was given to 1 child. The median duration of cytoreductive therapy was 24 (10.8–57.6) months. Before and during treatment as well as during follow-up, all the patients underwent following investigations: a complete blood count and biochemical blood test, the assessment of von Willebrand factor ristocetin cofactor (VWF:RCo) activity and allele burden, as well as ultrasound examination of liver and spleen.
Results
Before the initiation of cytoreductive therapy, platelet counts were extremely high in all the patients, with a median of 1427.5 (1134.5–2161.2) × 109/L; a reduced VWF:RCo activity ( 50%) was observed in 23 out of 24 children. Thirteen (54.2%) out of 24 patients had a response to cytoreductive therapy: a complete response was achieved in 5 cases (PEG-IFN-a – 4, HC – 1); a partial response was achieved in 8 patients (IFN-a/PEG-IFN-a – 5, HC – 2, anagrelide – 1). A decrease in platelet count was observed in 20 (79.2%) out of 24 patients: 10 (83%) out of 12 patients achieved a decrease in platelet count with PEG-IFN-a; 1 (50%) out of 2 children – with IFN-a; 8 (100%) children – with HC, and 1 (100%) child – with anagrelide. In the patient treated with anagrelide, normalization of platelet count was achieved 15 months after the initiation of treatment (from 2345 to 266 × 109/L). Treatment with ruxolitinib during 6 months resulted only in a slight decrease in platelet count (from 1342 to 987 × 109/L). The restoration of VWF:RCo activity occurred in parallel with a decrease in platelet count. Eight (66.7%) out of 12 patients treated with PEG-IFN-a showed a significant reduction in allele burden, and a minor increase was observed only in 2 cases. In 2 patients, the mutant allele frequency remained unchanged compared with that before cytoreductive therapy. Two patients treated with IFN-a also showed a decrease in allele burden. The median VAF (variant allele frequency) before the initiation of cytoreductive therapy with PEG-IFN-a was 12.8% (8.7–30.5%), and after treatment during 3–100 months (median 42 months) – 10.5% (6.5–25.2%) (p = 0.02). During HC therapy, an increase in VAF was observed in 3 out of 8 patients, in 1 case VAF remained unchanged, and only 4 children showed a decrease in VAF. During PEG-IFN-a therapy, adverse side effects in the form of influenza-like illness were observed only in 1 (8.3%) out of 12 patients, whereas during IFN-a therapy – in both patients (100%). In all cases, side effects did not exceed Grade 2 according to the CTCAE v.6.0 and did not require discontinuation of therapy. As regards the patients treated with HC, adverse side effects in the form of nausea were observed in 1 (12.5%) out of 8 patients.
Conclusion
When indicated, it is reasonable to use PEG-IFN-a as first-line therapy due to its high efficacy and favorable tolerability and safety profile.
Zitieren
APA
Kralichkin, P. V., Pshonkin, A. V., Zharkov, P. A., & Smetanina, N. S. (2026). Cytoreductive therapy in pediatric patients with essential thrombocythemia. Pediatric Hematology/Oncology and Immunopathology, 25(1), 60-67. https://doi.org/10.24287/j.1086
Vancouver
Kralichkin PV, Pshonkin AV, Zharkov PA, Smetanina NS. Cytoreductive therapy in pediatric patients with essential thrombocythemia. Pediatric Hematology/Oncology and Immunopathology. 2026;25(1):60-67. doi:10.24287/j.1086
BibTeX
@article{Kralichkin2026,
author = {Kralichkin, P. V. and Pshonkin, A. V. and Zharkov, P. A. and Smetanina, N. S.},
title = {Cytoreductive therapy in pediatric patients with essential thrombocythemia},
journal = {Pediatric Hematology/Oncology and Immunopathology},
year = {2026},
volume = {25},
number = {1},
pages = {60--67},
doi = {10.24287/j.1086}
}
EUVIMED